vs
Side-by-side financial comparison of HEARTLAND EXPRESS INC (HTLD) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
HEARTLAND EXPRESS INC is the larger business by last-quarter revenue ($179.4M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -10.8%, a 12.5% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -26.1%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -18.5%).
Heartland Express is an American trucking company headquartered in North Liberty, Iowa. The company offers truckload shipping services across the United States.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HTLD vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $179.4M | $177.4M |
| Net Profit | $-19.4M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -12.7% | 3.9% |
| Net Margin | -10.8% | 1.6% |
| Revenue YoY | -26.1% | 5.0% |
| Net Profit YoY | -949.2% | — |
| EPS (diluted) | $-0.24 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $179.4M | $196.9M | ||
| Q3 25 | $196.5M | $179.5M | ||
| Q2 25 | $210.4M | $181.1M | ||
| Q1 25 | $219.4M | $168.9M | ||
| Q4 24 | $242.6M | $187.3M | ||
| Q3 24 | $259.9M | $168.6M | ||
| Q2 24 | $274.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-19.4M | — | ||
| Q3 25 | $-8.3M | $5.4M | ||
| Q2 25 | $-10.9M | $-4.8M | ||
| Q1 25 | $-13.9M | $4.8M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $-9.3M | $-143.5M | ||
| Q2 24 | $-3.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -12.7% | 1.2% | ||
| Q3 25 | -3.7% | 3.5% | ||
| Q2 25 | -5.9% | 4.7% | ||
| Q1 25 | -6.8% | 1.2% | ||
| Q4 24 | 0.4% | 13.2% | ||
| Q3 24 | -2.7% | -82.8% | ||
| Q2 24 | 0.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -10.8% | — | ||
| Q3 25 | -4.2% | 3.0% | ||
| Q2 25 | -5.2% | -2.7% | ||
| Q1 25 | -6.3% | 2.8% | ||
| Q4 24 | -0.8% | — | ||
| Q3 24 | -3.6% | -85.1% | ||
| Q2 24 | -1.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.24 | $0.05 | ||
| Q3 25 | $-0.11 | $0.12 | ||
| Q2 25 | $-0.14 | $-0.11 | ||
| Q1 25 | $-0.18 | $0.10 | ||
| Q4 24 | $-0.03 | $0.38 | ||
| Q3 24 | $-0.12 | $-3.11 | ||
| Q2 24 | $-0.04 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.5M | $144.3M |
| Total DebtLower is stronger | $154.1M | — |
| Stockholders' EquityBook value | $755.3M | $653.9M |
| Total Assets | $1.2B | $1.2B |
| Debt / EquityLower = less leverage | 0.20× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $18.5M | $238.4M | ||
| Q3 25 | $32.7M | $246.3M | ||
| Q2 25 | $22.9M | $445.9M | ||
| Q1 25 | $23.9M | $493.6M | ||
| Q4 24 | $12.8M | $484.6M | ||
| Q3 24 | $30.7M | $453.8M | ||
| Q2 24 | $23.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $154.1M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $187.9M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $755.3M | $693.1M | ||
| Q3 25 | $775.6M | $727.2M | ||
| Q2 25 | $786.7M | $757.8M | ||
| Q1 25 | $807.7M | $798.5M | ||
| Q4 24 | $822.6M | $778.3M | ||
| Q3 24 | $825.7M | $749.6M | ||
| Q2 24 | $836.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.20× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.23× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.9M | — |
| Free Cash FlowOCF − Capex | $-44.2M | — |
| FCF MarginFCF / Revenue | -24.6% | — |
| Capex IntensityCapex / Revenue | 33.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-66.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $14.9M | $43.7M | ||
| Q3 25 | $27.5M | $60.8M | ||
| Q2 25 | $21.0M | $12.0M | ||
| Q1 25 | $25.8M | $35.5M | ||
| Q4 24 | $37.8M | $33.1M | ||
| Q3 24 | $35.6M | $53.9M | ||
| Q2 24 | $40.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-44.2M | $43.5M | ||
| Q3 25 | $-12.2M | $57.0M | ||
| Q2 25 | $-12.8M | $9.3M | ||
| Q1 25 | $2.3M | $26.9M | ||
| Q4 24 | $-45.5M | $31.0M | ||
| Q3 24 | $24.6M | $49.8M | ||
| Q2 24 | $29.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -24.6% | 22.1% | ||
| Q3 25 | -6.2% | 31.7% | ||
| Q2 25 | -6.1% | 5.1% | ||
| Q1 25 | 1.0% | 15.9% | ||
| Q4 24 | -18.8% | 16.6% | ||
| Q3 24 | 9.5% | 29.6% | ||
| Q2 24 | 10.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 33.0% | 0.1% | ||
| Q3 25 | 20.2% | 2.2% | ||
| Q2 25 | 16.1% | 1.5% | ||
| Q1 25 | 10.7% | 5.1% | ||
| Q4 24 | 34.3% | 1.1% | ||
| Q3 24 | 4.2% | 2.4% | ||
| Q2 24 | 3.8% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTLD
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
